Journal article · 2024 · Open access
Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs
Clinical Rheumatology, 43(6), 2133–2138 · Published 4 May 2024 · DOI 10.1007/s10067-024-06980-x
In brief
“Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs” is a 2024 journal article by M. Opdam and 7 co-authors, published in Clinical Rheumatology. OpenAlex counts 18 citations as of 19 November 2026. It is open access: the full text is free to read at Radboud Repository (Radboud University).
- Citations
- 18
- Most cited in
- 2025 (9)
- Field-weighted impact
- 4.08
- References
- 17
- Authors
- 8
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Opdam, M., Den Broeder, N., van den Bemt, B. J. F., Mulder, K., van de Wiel, K. M., van Ballegooijen, H., van Crevel, R., & den Broeder, A. A. (2024). Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clinical Rheumatology, 43(6), 2133–2138. https://doi.org/10.1007/s10067-024-06980-x
MLA 9
Opdam, M., et al. “Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.” Clinical Rheumatology, vol. 43, no. 6, 2024, pp. 2133–2138. https://doi.org/10.1007/s10067-024-06980-x.
Chicago
Opdam, M., N. Den Broeder, Bart J. F. van den Bemt, Kelly Mulder, Kayleigh M van de Wiel, Hanne van Ballegooijen, Reinout van Crevel, and Alfons A den Broeder. 2024. “Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.” Clinical Rheumatology 43 (6): 2133–2138. https://doi.org/10.1007/s10067-024-06980-x.
Harvard
Opdam, M. et al. (2024) ‘Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs’, Clinical Rheumatology, 43(6), pp. 2133–2138. doi:10.1007/s10067-024-06980-x.
IEEE
M. Opdam et al., “Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs,” Clinical Rheumatology, vol. 43, no. 6, pp. 2133–2138, 2024, doi: 10.1007/s10067-024-06980-x.
BibTeX
@article{opdam2024higher,
title = {{Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs}},
author = {Opdam, M. and Den Broeder, N. and van den Bemt, Bart J. F. and Mulder, Kelly and van de Wiel, Kayleigh M and van Ballegooijen, Hanne and van Crevel, Reinout and den Broeder, Alfons A},
journal = {Clinical Rheumatology},
year = {2024},
volume = {43},
number = {6},
pages = {2133--2138},
doi = {10.1007/s10067-024-06980-x},
url = {https://doi.org/10.1007/s10067-024-06980-x}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 1 | |
| 2025 | 9 | |
| 2026 | 8 |
Its field-weighted citation impact is 4.08: it has been cited 4.08 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- tofacitinib
- baricitinib
- biologic DMARDs
- infection risk
- herpes zoster
- antibiotic prescribing
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Opdam, M., Den Broeder, N., van den Bemt, B. J. F., Mulder, K., van de Wiel, K. M., van Ballegooijen, H., van Crevel, R., & den Broeder, A. A. (2024). Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clinical Rheumatology, 43(6), 2133–2138. https://doi.org/10.1007/s10067-024-06980-x
How many times has this paper been cited?
18 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Radboud Repository (Radboud University): sign in and open the PDF from this page.
Who wrote this paper?
M. Opdam, N. Den Broeder, Bart J. F. van den Bemt, Kelly Mulder, Kayleigh M van de Wiel, Hanne van Ballegooijen, Reinout van Crevel, Alfons A den Broeder.
What is the DOI of this paper?
10.1007/s10067-024-06980-x, permanently at https://doi.org/10.1007/s10067-024-06980-x. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.